Read Frequently Asked Questions
Superiority, Non-inferiority, or Equivalence Trials: How, Why and When
This webinar on clinical study design will explore the differences among superiority, Non-inferiority (NI), and equivalence trials, including development of the precise research questions necessary to making a decision about appropriate clinical designs.
Why Should You Attend:
Randomized Control Trials (RCT) aimed at showing superiority remain the gold standard in clinical trial research, but are not appropriate for trials in which the aim is to show that a new treatment is equivalent or at least non-inferior to the current standard of care. The design of non-inferiority (NI) and equivalence trials is not as straightforward as that of the RCT superiority trial, and requires precise definitions of the interval of equivalence and/or region of non-inferiority.
This session will explore the differences among superiority, NI, and equivalence trials, including development of the precise research questions necessary to making a decision about appropriate clinical designs. The instructor will examine details of representative studies and review relevant FDA guidances.
Areas Covered in the Webinar:
- Overview and comparison of NI, equivalence, and superiority study objectives and designs.
- Zeroing in on the specific clinical question to be asked.
- Choosing the appropriate design to answer the specific clinical question.
- How to determine the appropriate interval of equivalence or acceptable “margin” of inferiority.
- Appropriate hypothesis tests and statistical interpretation. (for nonstatisticians)
- Risk of “BioCreep” and other controversies associated with these alternative approaches.
- FDA guidance and CONSORT considerations.
Who will Benefit:
Professionals who will benefit from this webinar include:
- Clinical Research Professionals
- Clinical Protocol Developers
- Clinical Study Managers
- Regulatory Managers
- Clinical Studies Directors
- Anyone who seeks to design appropriate clinical investigations for supporting anticipated labeling for a new drug or medical device.
Dr. Hanover, has worked in clinical research for over 30 years, as a Principal Investigator for studies funded by national agencies such as NIMH, Veteran’s Affairs, and DOD as well as various private pharmaceutical and medical device companies, as a Professor teaching research methods, biostatistics, and evidence-based medicine at the University of Utah School of Medicine, a Consultant to the Utah State Department of Health, and Director of Clinical Research for Techniscan Medical Systems. She has concurrently held consulting positions for such companies as Pherin Pharmaceuticals, Utah Cancer Specialists, Montgomery-Watson Environmental Engineering, and Planned Parenthood Federation of America. She earned a Regulatory Affairs Certification (RAC) in 2006 through RAPS, and is also a member of the Society of Clinical Research Associates (SOCRA), and the American Statistical Association (AMSTAT).
Non-inferiority (NI) clinical trials offer distinct advantages and are often the most appropriate way to evaluate new treatments being compared to accepted standard treatments. Even though they are increasingly used for this purpose there are valid criticisms that must be addressed, and regulatory standards will continue to evolve around statistical, ethical and evidence-based considerations.
This webinar is directed toward professionals in two broad groups. For those on the side of new drug/device developments that may have safety, ease of administration, or economic or advantages over current treatment, this discussion will explain nontraditional clinical trial designs necessary for indication designation and labeling. For those who need to intelligently evaluate clinical study design and outcome, for business, regulatory, or evidence-based medical decisions, this is a discussion about how to determine the adequacy and merit of a particular study.
The pharmaceutical and medical device industry increasingly faces the challenge of launching ever more safe and efficient drugs and devices on the market. This often means looking for drugs at least as efficacious, but with some treatment advantage, over those already available, for example, or devices that are less expensive or easier to operate.
ComplianceOnline would process/provide refund only if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs."
For substitution, please email firstname.lastname@example.org or call +1-650-620-3937.
This training hasn't been reviewed yet.
Non-inferiority Trials: Practical Issues and Current Regulatory Perspectives Writing and Implementing Statistical Analysis Plans (SAPs) - Domestic and International Guidance under ICH E9